Skip to content
Home/Companies/Biotech/Symphogen

Symphogen

Biotech·Denmark·Exited 2020·Held 1yr
Entry
2019
Hold
1yr
Exit
2020

Who owns Symphogen?

Symphogen is a Danish Biotech company, now owned by Servier, which acquired it in 2020 from Sunstone Life Science Ventures.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Sunstone Life Science Ventures
Investor
Sunstone Life Science Ventures
Sunstone Life Science Ventures IV · 2015 · VC

Key facts

HQDenmark
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
Servier
Exit Year
2020

More from Sunstone Life Science Ventures IV

Other portfolio companies in the same fund.

Oblique Therapeutics
Active
BiotechSweden· 2020
Synendos Therapeutics
Synendos Therapeutics
Active
BiotechSwitzerland· 2020
Forendo Pharma
Exited 2021
BiotechFinland· 2019
to Organon
STipe Therapeutics
Exited 2024
BiotechDenmark· 2019
OxThera
OxThera
Active
BiotechSweden· 2016
IO Biotech
IO Biotech
Exited 2021
BiotechDenmark· 2015

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Symphogen?

Symphogen is now owned by Servier, which acquired it in 2020 from Sunstone Life Science Ventures.

When did Servier acquire Symphogen?

Servier acquired Symphogen in 2020, buying from Sunstone Life Science Ventures.

Who did Symphogen sell to?

Sunstone Life Science Ventures sold Symphogen to Servier in 2020 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue